First-in-human study of EP102 in advanced solid tumors initiated
The first-in-human study for EP102 aims to evaluate safety, tolerability, and antitumor activity in advanced solid tumors.
Therapeutic Area
Therapeutic area intelligence for Solid Tumors with 12 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.